Investigator
Associate Consultant · National University Cancer Institute, Singapore, Haematology-Oncology
Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer
This study is phase II, open label, clinical trial to determine the efficacy of Olaparib maintenance with Bevacizumab and Pembrolizumab by assessment progression-free survival(6 months PFS rate) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer.
Associate Consultant
National University Cancer Institute, Singapore · Haematology-Oncology
M.B.B.S (Hons)
National University Singapore Yong Loo Lin School of Medicine
